511 related articles for article (PubMed ID: 18418527)
21. Diagnostic significance of CK19, RET, galectin-3 and HBME-1 expression for papillary thyroid carcinoma.
Zhu X; Sun T; Lu H; Zhou X; Lu Y; Cai X; Zhu X
J Clin Pathol; 2010 Sep; 63(9):786-9. PubMed ID: 20644217
[TBL] [Abstract][Full Text] [Related]
22. Galectin-3 is not useful in thyroid FNA.
Mills LJ; Poller DN; Yiangou C
Cytopathology; 2005 Jun; 16(3):132-8. PubMed ID: 15924608
[TBL] [Abstract][Full Text] [Related]
23. Intensity and distribution of immunohistochemical expression of galectin-3 in thyroid neoplasms.
Matesa-Anić D; Moslavac S; Matesa N; Cupić H; Kusić Z
Acta Clin Croat; 2012 Jun; 51(2):237-41. PubMed ID: 23115948
[TBL] [Abstract][Full Text] [Related]
24. [Expression of cytokeratin19, galectin-3 and HBME-1 in thyroid lesions and their differential diagnoses].
Teng XD; Wang LJ; Yao HT; Li J; Ding W; Yan LP
Zhonghua Bing Li Xue Za Zhi; 2004 Jun; 33(3):212-6. PubMed ID: 15256110
[TBL] [Abstract][Full Text] [Related]
25. Changes in galectin-7 and cytokeratin-19 expression during the progression of malignancy in thyroid tumors: diagnostic and biological implications.
Rorive S; Eddafali B; Fernandez S; Decaestecker C; André S; Kaltner H; Kuwabara I; Liu FT; Gabius HJ; Kiss R; Salmon I
Mod Pathol; 2002 Dec; 15(12):1294-301. PubMed ID: 12481010
[TBL] [Abstract][Full Text] [Related]
26. Retinoblastoma expression in thyroid neoplasms.
Anwar F; Emond MJ; Schmidt RA; Hwang HC; Bronner MP
Mod Pathol; 2000 May; 13(5):562-9. PubMed ID: 10824929
[TBL] [Abstract][Full Text] [Related]
27. [Low galectin-3 capacity to discriminate thyroid lesions].
De-León-Mazariegos R; Canedo-Patzi M; Pérez-Enríquez B; Candanedo-Gonzalez F; Saqui-Salces M; Gamboa-Domínguez A; Rull-Rodrigo JA
Rev Invest Clin; 2004; 56(5):623-8. PubMed ID: 15776867
[TBL] [Abstract][Full Text] [Related]
28. Expression of cytokeratin 19, HBME-1 and galectin-3 in neoplastic and nonneoplastic thyroid lesions.
Mataraci EA; Ozgüven BY; Kabukçuoglu F
Pol J Pathol; 2012 Mar; 63(1):58-64. PubMed ID: 22535608
[TBL] [Abstract][Full Text] [Related]
29. The efficacy of the thyroid peroxidase marker for distinguishing follicular thyroid carcinoma from follicular adenoma.
Savin S; Cvejic D; Isic T; Paunovic I; Tatic S; Havelka M
Exp Oncol; 2006 Mar; 28(1):70-4. PubMed ID: 16614712
[TBL] [Abstract][Full Text] [Related]
30. Galectin-3 and proliferating cell nuclear antigen (PCNA) expression in papillary thyroid carcinoma.
Cvejic D; Savin S; Petrovic I; Selemetjev S; Paunovic I; Tatic S; Havelka M
Exp Oncol; 2005 Sep; 27(3):210-4. PubMed ID: 16244583
[TBL] [Abstract][Full Text] [Related]
31. Assessment of cyclin D1 gene expression as a prognostic factor in benign and malignant thyroid lesions.
Brzeziańska E; Cyniak-Magierska A; Sporny S; Pastuszak-Lewandoska D; Lewiński A
Neuro Endocrinol Lett; 2007 Aug; 28(4):341-50. PubMed ID: 17693985
[TBL] [Abstract][Full Text] [Related]
32. Galectin-3 expression in papillary microcarcinoma of the thyroid.
Cvejic D; Savin S; Petrovic I; Paunovic I; Tatic S; Krgovic K; Havelka M
Histopathology; 2005 Aug; 47(2):209-14. PubMed ID: 16045783
[TBL] [Abstract][Full Text] [Related]
33. Expression of cell-cycle regulators (cyclin D1, cyclin E, p27kip1, p57kip2) in papillary thyroid carcinoma.
Lee SH; Lee JK; Jin SM; Lee KC; Sohn JH; Chae SW; Kim DH
Otolaryngol Head Neck Surg; 2010 Mar; 142(3):332-7. PubMed ID: 20172376
[TBL] [Abstract][Full Text] [Related]
34. Galectin-3 is highly expressed in nonencapsulated papillary thyroid carcinoma but weakly expressed in encapsulated type; comparison with Hector Battifora mesothelial cell 1 immunoreactivity.
Torregrossa L; Faviana P; Camacci T; Materazzi G; Berti P; Minuto M; Elisei R; Vitti P; Miccoli P; Basolo F
Hum Pathol; 2007 Oct; 38(10):1482-8. PubMed ID: 17597183
[TBL] [Abstract][Full Text] [Related]
35. Galectin-3 expression in various thyroid neoplasms and its possible role in metastasis formation.
Kawachi K; Matsushita Y; Yonezawa S; Nakano S; Shirao K; Natsugoe S; Sueyoshi K; Aikou T; Sato E
Hum Pathol; 2000 Apr; 31(4):428-33. PubMed ID: 10821488
[TBL] [Abstract][Full Text] [Related]
36. Analysis of P161NK4A protein expression in follicular thyroid tumors.
Ferenc T; Lewiński A; Lange D; Niewiadomska H; Sygut J; Sporny S; Jarzab B; Sałacińska-Loś E; Kulig A; Włoch J
Pol J Pathol; 2004; 55(4):143-8. PubMed ID: 15757201
[TBL] [Abstract][Full Text] [Related]
37. Galectin-3 expression in papillary thyroid carcinoma: relation to histomorphologic growth pattern, lymph node metastasis, extrathyroid invasion, and tumor size.
Cvejic DS; Savin SB; Petrovic IM; Paunovic IR; Tatic SB; Havelka MJ
Head Neck; 2005 Dec; 27(12):1049-55. PubMed ID: 16155918
[TBL] [Abstract][Full Text] [Related]
38. Analysis of P53 and P21WAF1 proteins expression in follicular thyroid tumors.
Ferenc T; Lewiński A; Lange D; Niewiadomska H; Sygut J; Sporny S; Jarzab B; Sałacińska-Loś E; Kulig A; Włoch J
Pol J Pathol; 2004; 55(4):133-41. PubMed ID: 15757200
[TBL] [Abstract][Full Text] [Related]
39. The expression and role of serum response factor in papillary carcinoma of the thyroid.
Kim HJ; Kim KR; Park HS; Jang KY; Chung MJ; Shong M; Moon WS
Int J Oncol; 2009 Jul; 35(1):49-55. PubMed ID: 19513551
[TBL] [Abstract][Full Text] [Related]
40. Molecular phenotyping of thyroid tumors identifies a marker panel for differentiated thyroid cancer diagnosis.
Wiseman SM; Melck A; Masoudi H; Ghaidi F; Goldstein L; Gown A; Jones SJ; Griffith OL
Ann Surg Oncol; 2008 Oct; 15(10):2811-26. PubMed ID: 18612701
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
